BRCA2 and ovarian carcinoma: For ovarian cancer patients with optimal cytoreduction, combined expression of MAGEC3 and BRCA2 showed that patients that were BRCA2 expressors with MAGEC3 loss levels had better overall and progression-free survival compared with patients who were BRCA2 expressors with normal MAGEC3 levels.